The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-migraine Headaches

Objectives: FDA has approved Onabotulinum toxin type A (BoNTA) for prophylactic treatment of chronic migraines. Recent studies have explored its potential new indications, like treating post-traumatic headaches. Patients and Methods: This is a retrospective chart review of 717 patients, who had fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Cassie, Lucchese, Scott, Zhang, Fang, Govindarajan, Raghav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763695/
https://www.ncbi.nlm.nih.gov/pubmed/31616362
http://dx.doi.org/10.3389/fneur.2019.01009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763695/
https://www.ncbi.nlm.nih.gov/pubmed/31616362
http://dx.doi.org/10.3389/fneur.2019.01009

Ejemplares similares